Skip Navigation


JAC Advance Access originally published online on January 13, 2005
Journal of Antimicrobial Chemotherapy 2005 55(2):275-276; doi:10.1093/jac/dkh539
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/2/275    most recent
dkh539v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Majoros, L.
Right arrow Articles by Maráz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Majoros, L.
Right arrow Articles by Maráz, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.55 no.2 © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved

Correspondence

Fluconazole susceptibility testing of Candida inconspicua clinical isolates: comparison of four methods

L. Majoros1, G. Kardos1, B. Szabó1,2, M. Kovács3 and A. Maráz3

1 Department of Medical Microbiology, Medical and Health Science Center, University of Debrecen; 2 Faculty of Health Sciences, Medical and Health Science Center, University of Debrecen; 3 Department of Microbiology and Biotechnology, Faculty of Food Science, Corvinus University of Budapest, Budapest, Hungary

* Corresponding author.Email: major@jaguar.dote.hu

Keywords: C. inconspicua , Etest , Fungitest , broth microdilution , NCCLS

The first 10% of the full text of this article appears below.

Sir,

During the past 4 years, isolation of Candida inconspicua from clinical samples has increased in our laboratory.1 Fluconazole MIC values for C. inconspicua isolates are relatively high, as determined by standard broth microdilution (BMD), Etest or Fungitest,2–4 and according to the standard BMD method they fall mainly into the susceptible-dose dependent (S-DD) or resistant (R) categories, with few susceptible (S) isolates.1–3

Since fluconazole is the most widely used drug in the clinical setting, and in the case of rare Candida species . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
M. A. Pfaller and D. J. Diekema
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Majoros, G. Kardos, B. Szabo, and M. Sipiczki
Caspofungin Susceptibility Testing of Candida inconspicua: Correlation of Different Methods with the Minimal Fungicidal Concentration
Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3486 - 3488.
[Abstract] [Full Text] [PDF]